Scarica l'app Stockscreener
122.97
0.10%
0.12
Dopo l'orario di chiusura:
122.97
Precedente Chiudi:
$122.85
Aprire:
$122.85
Volume 24 ore:
1.40M
Relative Volume:
2.21
Capitalizzazione di mercato:
$7.43B
Reddito:
$3.99B
Utile/perdita netta:
$463.16M
Rapporto P/E:
-78.32
EPS:
-1.57
Flusso di cassa netto:
$1.10B
1 W Prestazione:
-0.06%
1M Prestazione:
+3.13%
6M Prestazione:
+14.54%
1 anno Prestazione:
+2.71%
Intervallo 1D:
$121.37
$124.39
Intervallo di 1 settimana:
$119.14
$126.23
Portata 52W:
$99.06
$134.17
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
122.97 | 7.43B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Sanctuary Advisors LLC Buys 9,804 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Jazz Pharmaceuticals CEO to retire by end 2025, search begins - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $2.49 Million Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals CEO to Present Strategic Vision at JP Morgan Healthcare Conference 2025 - StockTitan
Big Peninsula drugmaker on the hunt for new CEO - The Business Journals
Jazz Pharmaceuticals CEO to Retire, Succession Search Underway - Sleep Review
Graft-Versus-Host Disease Market on Track for Major Expansion - openPR
Jazz Pharmaceuticals Announces CEO Succession Plan - PharmiWeb.com
Jazz Pharmaceuticals CEO to retire - MSN
Bruce Cozadd to retire as Jazz’s CEO - BioCentury
Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 - Marketscreener.com
Jazz Pharmaceuticals CEO to retire by end of 2025 - Investing.com South Africa
Jazz to search for new chief as CEO plans retirement - BioPharma Dive
Jazz Pharmaceuticals CEO to Step Down After Two Decades of Transformative Leadership - StockTitan
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Raised by Franklin Resources Inc. - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist? - Yahoo Finance
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch - Yahoo Finance
Morgan Stanley boosts Jazz Pharmaceuticals stock rating, sees upside with Ziihera launch - Investing.com Nigeria
Jazz Pharmaceuticals retains stock target, Overweight rating on FDA approval By Investing.com - Investing.com Nigeria
Morgan Stanley upgrades Jazz Pharmaceuticals shares, highlights Ziihera’s growth potential - Investing.com Nigeria
Morgan Stanley Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to "Overweight" - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - MarketBeat
State Street Corp Sells 71,036 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Y Intercept Hong Kong Ltd Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Stifel Financial Corp Has $15.83 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Jane Street Group LLC - MarketBeat
Jazz Pharmaceuticals Showcases Evidence Reinforcing Epidiolex (CBD) Medical Benefits - Cannabis Business Times
Two Sigma Advisers LP Purchases 84,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements - Benzinga
XTX Topco Ltd Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $175.33 - MarketBeat
BNP Paribas Financial Markets Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Quantinno Capital Management LP Boosts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Celebrating International Volunteers Day: Honoring the Impa - CSRwire.com
Jazz Pharma's Epidiolex Shows Remarkable 87% Seizure Reduction in Real-World Epilepsy Studies - StockTitan
Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Point72 Asset Management L.P. Acquires 86,768 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Fmr LLC Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Bank of Montreal Can Sells 49,214 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Insider Sell: Bruce Cozadd Sells 2,000 Shares of Jazz Pharmaceuticals PLC - GuruFocus.com
Jazz Pharma's Groundbreaking Cancer Drug Ziihera Secures NCCN Guidelines Recognition After FDA Approval - StockTitan
Systematic Financial Management LP Purchases 29,647 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Centiva Capital LP - MarketBeat
Jazz Pharmaceuticals' chief accounting officer sells $6,491 in shares By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares By Investing.com - Investing.com Canada
Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares - Investing.com
Jazz Pharmaceuticals to Showcase Breakthrough Cancer Drug Ziihera Following FDA Approval - StockTitan
Parkman Healthcare Partners LLC Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jazz Pharmaceuticals Plc Azioni (JAZZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Carr Patricia | SVP, Chief Accounting Officer |
Dec 02 '24 |
Sale |
122.49 |
53 |
6,492 |
6,596 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):